This year! 78 pharmaceutical companies have shown | 'report card'

According to statistics, a total of 78 pharmaceutical companies disclosed the 2017 annual performance notice, of which 52 pre-release Increase, 2 pre-profit, 6 flat, 7 pre-reduction, a pre-losing.

A shares of 2017 annual results of pharmaceutical companies at a glance (unit: million)

Source: Oriental Fortune Network

Statistics as of November 14

According to Livzon Group's 2017 annual results notice, the net profit attributable to shareholders of listed companies was RMB4,322,017.17 -447,517.44 million, an increase of 451.04% -470.56% over the same period of last year. For the substantial growth in performance, Livzon Group said that the Company and its subsidiaries The Company's wholly-owned subsidiary of Livzon Pharmaceutical Group Co., Ltd. transferred 100% equity of Zhuhai Weixing Industrial Co., Ltd. The share transfer was completed on July 17, 2017. It is expected that the transaction will increase the net profit attributable to shareholders of the listed company About 3498000000 yuan.In addition, the company business sales in all fields to maintain steady growth, but also operating income and profits continued to grow steadily one of the factors.

Some analysts pointed out that the rapid development of bio-drug plate Livzon Group, monoclonal antibody worth the wait. Recombinant human vinxins (not monoclonal antibody, monoclonal antibody platform research and development) is expected to report the second quarter of 2018 production; TNF-α Clinical phase Ⅱ has been enrolled in dozens of cases, is expected to be completed in the first half of next year, is the only humanized products in the market research; CD20 analogs exempt from phase Ⅱ clinical, the company exactly in accordance with the correct sequence and new technology imitation, and the original research is very similar ; HER2 project has launched phase Ⅰ clinical trial study, the product can be combined with Herceptin, less competition; PD-1 project the United States clinical phase Ⅰ second dose has been most of the group; IL17A + F dual-function antibody, adapted The disease is very wide, is expected to become the world's Best-in-class.

Shuangcheng Pharmaceutical disclosed the third quarter report of 2017, the company's first three quarters of this year is still in a loss-making results, the annual net profit of 800 million -1200.00 million, an increase of 102.06% ~ 103.09%, will turn around, The loss of up to 388 million in 2016. Shuangcheng Pharmaceutical said the main reason for profitability is: in 2017 the company management through the introduction of new products, cost control, integration of sales resources, optimize research and development projects, the disposal of inefficient assets and other measures, effective Expansion of sales, reducing costs, so that operating efficiency and significantly improved over the same period last year.

It is understood that the future Shuangcheng Pharmaceutical is still targeting the international strategy.On the one hand, with the improvement of research and development strength, with the introduction of the relevant species to develop the corresponding overseas declaration and other work, and to achieve the original level of domestic research drug Bidding Work to create favorable conditions.In recent years the company research and development of peptide products nearly 10, these projects are in different stages of research and development, in the process of internationalization of polypeptide varieties is the focus of research and development projects.On the other hand, actively carry out cooperation with foreign enterprises through the patent The right to license, cooperation and development, such as the acquisition of a controlling stake in the advanced foreign innovative drugs or domestic sales of large products introduced to the country.

Yifan Medicine estimates that the net profit attributable to shareholders of listed companies will fluctuate by RMB1,162,858,500-1,374,287,300 in FY17, representing an increase of 65% -95% over the same period of last year, mainly due to the increase in the Company's vitamin B5 series products over the same period of previous year Increase.

It is worth mentioning that a few days ago, Yi Fan Pharmaceutical and Wholly-owned subsidiary of Fanlai International and Merrylake signed an agreement on the purchase of assets in cash, the company intends to increase the International Fanfan International 20,600,000 US dollars (according to November 2, 2017 exchange rate (Equivalent to RMB136 million) for the 100% shareholding of NovoTek Pharmaceuticals Limited ("NovoTek") held by Merrylake Inc. After the completion of the transaction, Everfinite will hold NovoTek's 100% stake in NovoTek will become the company's wholly-owned subsidiary of Sun. Bulletin said that billion sail medicine will be able to force the subject of the company in the field of global formulation of the international team, with well-known pharmaceutical companies good cooperation resources and business negotiation experience, have The imported product resources listed in China open the channel for the follow-up companies to continue to import imported products to further enrich the product structure of the Company and to achieve drug Preparation of international strategy to lay a solid foundation.

Xinhecheng estimates that the net profit attributable to shareholders of the listed company in 2017 ranged from RMB144,161,200 to RMB1,803,950,300, representing an increase of 20% -50% over the same period of last year. The performance growth was mainly attributable to the changes in the number and prices of sales of leading products of the Company as compared with the same period of last year.

Some analysts pointed out that the new and into the third quarter, the main product of vitamin prices rose sharply, the implementation of high-priced orders in the fourth quarter led to substantial growth in performance.In addition, the nutritional supplements in the plate, the company's 50,000 tons methionine project full, Methionine Phase II 100,000 tons is expected to be put into production in the first half of 2019 and the subsequent 150,000 tons Methionine project will enter the market in 2021. The new flavors and fragrances continue to be put into production with continuous growth of 3,000 tons of maltol and 3,000 tons of ionone expected to be put into operation in 2018 , The company cost control ability.New material plate PPS second 10,000 tons put into operation, and DSM joint application of the pioneering, will bring revenue growth for the company.

As of now, from medicine enterprise Disclosure of the 2017 annual performance forecast point of view, most companies are reaping full successor will have more companies will gradually disclose the performance of the situation, then in the end what the performance of the pharmaceutical companies to be able to dispel the courageous and fastest growing, What is the highest gross profit margin? We will wait and see.